EXCELLENT EFFICACY OF DIRECT ACTING ANTIVIRALS (DAAS) AMONG PEOPLE WHO INJECT DRUGS (PWID): EXPERIENCE FROM THE LARGEST EXPERTIZED GREEK CENTER

TSIROGIANNI E[1,2], OIKONOMOU T[2], PROTOPAPAS A[2], TSEKOURA P[1], TANIS C[1], ANDROULAKIS G[1], STAVRIDOU V[1], CHATZIDIMOU M[1], FOTAKIDOU C[1], DELIMANI E[1], PAPATHANIASIOU I[1], LOLA A[1], KOUKOUFIKI A[2], PERLEPE N[2], GOULIS I[2]

[1]NATIONAL ORGANIZATION AGAINST DRUGS, OKANA, THESSALONIKI, GREECE
[2]FOURTH DEPARTMENT OF INTERNAL MEDICINE, ARISTOTLE UNIVERSITY OF THESSALONIKI, HIPPOKRATION GENERAL HOSPITAL, THESSALONIKI, GREECE

BACKGROUND

TREATMENT OF HEPATITIS C AMONG PWID, ESPECIALLY WITH DAAS, CONSTITUTES SIGNIFICANT TARGET TOWARDS THE ELIMINATION OF THE DISEASE WORLDWIDE. WE PRESENT DATA FROM AN EXPERTIZED HEPATOLOGY CLINIC THAT MANAGES ONLY PWID.

METHODS

WE INCLUDED PATIENTS EXAMINED IN OUR HEPATOLOGY CLINIC WHOFULFILLED THE NATIONAL CRITERIA FOR DAA REIMBURSEMENT (POSITIVE HCV RNA, ≥ F2 ON FIBROSCAN). ALL WERE EITHER ACTIVE OR EX- INTRAVENOUS DRUG USERS. SOME OF THEM WERE INTEGRATED IN DETOXIFICATION OR SUBSTITUTION PROGRAMS. THEY WERE ALL TREATED WITH DAAS, ACCORDING WITH THE GUIDELINES TARGETING TO SUSTAINED VIRAL RESPONSE AT THE TIME POINT OF 12 WEEKS AFTER END OF TREATMENT (SVR12).

RESULTS

ONE HUNDRED THIRTY FIVE PATIENTS [122/135 MALES (90.3%), AGE 43YEARS (79±10)] WERE INCLUDED.

103/135 (76,3%) WERE MANAGED THROUGH THE NATIONAL ORGANIZATION AGAINST DRUGS CALLED OKANA. 85/103 (82.5%) RECEIVED SUBSTITUTION WITH BUPRENORPHINE, 18/103 (17.48%) WITH METHADONE, 23/135 (17.04%) WERE IN OTHER DETOXIFICATION PROGRAMS (ΚΕΘΕΑ, ΨΝΘ, NA) AND 9/135 (6.67%) RECEIVED NO SUPPORT.

HCV GENOTYPE DISTRIBUTION INCLUDED :
1A: 17.04%,
1B: 12.59%,
2: 5.19%,
3A: 58.52%,
4: 6.67%.



THE DAA REGIMENS PATIENTS RECEIVED WERE:
SOFOSBUVIR/VELPATASVIR: 46.67%
SOFOSBUVIR/VELPATASVIR+RIBAVIRIN: 10.37%
SOFOSBUVIR/LEDIPASVIR: 5.93%
SOFOSBUVIR/LEDIPASVIR+RIBAVIRIN: 1.48%
SOFOSBUVIR+DACLATASVIR: 5.19%,
SOFOSBUVIR+DACLATASVIR+RIBAVIRIN: 5.19%,
PARITAPREVIR/RITONAVIR/OMBITASVIR+RIBAVIRIN: 2.96%,
PARITAPREVIR/RITONAVIR/OMBITASVIR+DASABUVIR: 1.48%
PARITAPREVIR/RITONAVIR/OMBITASVIR+DASABUVIR+RIBAVIRIN: 6.67%,
GRAZOPREVIR/ELBASVIR: 15.56%.



OUT OF THE 135 PATIENTS INCLUDED, 90 (66.67%) COMPLETED ANTIVIRAL TREATMENT, 39 (28.89%) ARE STILL UNDER TREATMENT AND 6 (4.44%) PREMATURELY DISCONTINUED TREATMENT. SVR12 RATES FOR THE FIRST 54 PATIENTS WHO COMPLETED POST-TREATMENT FOLLOW-UP WAS 100%.
5 OUT OF 6 PATIENTS WHO DISCONTINUED TREATMENT WERE UNDER SUBSTITUTION PROGRAMS; 4 ACHIEVED SVR12, 3 WERE TREATED WITH SOFOSBUVIR/VELPATASVIR FOR 2 MONTHS AND ONE WITH PARITAPREVIR/RITONAVIR/OMBITASVIR+DASABUVIR FOR 1 MONTH. THOSE TWO WHO DID NOT ACHIEVE SVR12, DISCONTINUED TREATMENT DURING THE FIRST MONTH AND RECEIVEDGRAZOPREVIR/ELBASVIRAND PARITAPREVIR/RITONAVIR/OMBITASVIR+RIBAVIRIN, RESPECTIVELY.

CONCLUSION

TREATMENT OF HEPATITIS C WITH NEW DAAS IN EXPERTIZED HEPATOLOGY CLINICS SHOWS EXCELLENT EFFICACY AND HIGH COMPLIANCE IN PWID.